HUMA news

Latest 1 stories · newest Jun 10, 2026

HUMA

Humacyte's ATEV met Phase 3 primary endpoint vs AV fistula in dialysis study

Humacyte announced positive interim results from its V012 Phase 3 study showing the acellular tissue engineered vessel (ATEV) achieved superior catheter-free days (91 more days, p=0.00070) compared to standard autologous AV fistula in female dialysis patients. The company plans to file a supplementa…

Regulatory Jun 10, 2026 sentiment +0.92 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same HUMA feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/HUMA/newsSTART FREE